Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta2-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). CONCLUSIONS: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In earlier randomized trials, an improvement in OS was seen in two studies,132,133 but other studies failed to show such an improvement.134,135”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [132]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Research works printed but not linked: 7
- Barlogie B, 1991, Bone Marrow Transplant, 7, 71
- Fermand J-P, 1999, Blood, 94, 396a
- Blade J, 2001, Blood, 98, 815a
- Palumbo A, 2001, Blood, 98, 849a
- Fermand J-P, 2001, Blood, 98, 815a
- Richardson P, 2002, Blood, 100, 104a
- Sirohi B, 2002, Bone Marrow Transplant, 29, S12
Cited by
Items 601–700 of 987
Deola, S., Scaramuzza, S., Birolo, R. S., Cergnul, M., Ficara, F., Dando, J., Voena, C., Vai, S., Monari, M., Pogliani, E., et al. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-35 · Cited by 8
“The standard therapy for multiple myeloma is high-dose chemotherapy with autologous reinfusion of hematopoietic stem cells [ 1-3 ].”
Ray, G. K., Jena, R. K., Panda, T., & Sethy, S. (2020) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2020.04.011 · Cited by 8
Straka, C., Salwender, H. J., Knop, S. T., Vogel, M., Müller, J., Metzner, B., Langer, C., Sayer, H. G., Jung, W. E., Dürk, H., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13690 · Cited by 10
Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey
Olivieri, J., Pierelli, L., Introna, M., Accorsi, P., Bosi, A., Perseghin, P., Risso, M., Pandolfi, A., Mancini, S., Marchetti, M., et al. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.07.001 · Cited by 8
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma
Kröger, N. M. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500080850 · Cited by 8
Martino, M. V., Console, G., Irrera, G., Praticò, G., Stelitano, C. C., Callea, V., Morabito, F., Quartarone, E., Musolino, C., Piro, E., et al. (2006) · American Journal of Hematology · doi:10.1002/ajh.20677 · Cited by 8
“compared with a single APBSCT [5].”
Kennedy, G., Butler, J., Morton, J., Hill, G. R., Western, R., Cummings, J. Y., Allison, R., & Durrant, S. (2006) · Clinical & Laboratory Haematology · doi:10.1111/j.1365-2257.2006.00773.x · Cited by 8
Yamada, T., Tomonari, A., Takahashi, S., Ooi, J., Iseki, T., Shimohakamada, Y., Takasugi, K., Ohno, N., Nagamura, F., Uchimaru, K., et al. (2004) · International Journal of Hematology · doi:10.1532/ijh97.04091 · Cited by 8
“Moreover, a tandem therapeutic regimen of HDT with ASCT may be more beneficial than a single use of HDT with ASCT [3].”
BackgroundCzyż, J., Dziadziuszko, R., Knopińska‐Posłuszny, W., Hellmann, A. R., Kachel, L., Hołowiecki, J., Czyż, A., Komarnicki, M., Osowiecki, M., Walewski, J. A., et al. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190601158621 · Cited by 8
“Data obtained from a large randomized trial in patients with multiple myeloma demonstrated a significant improvement in OS for double HDC followed by stem-cell transplantation [24].”
BackgroundCD4+ T lymphocyte counts after autologous transplantation in multiple myeloma: A retrospective study
Gorschlüter, M., Glasmacher, A., Sarazin, S., Hackbarth, F., Hoebert, E., Orlopp, K. S., Schmidt‐Wolf, I. G. H., & Mey, U. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190601094347 · Cited by 8
Chng, W. J., & Fonseca, R. (2005) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2005.n.047 · Cited by 8
The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma
Bensinger, W. (2004) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2004.0030 · Cited by 8
“A randomized trial that compared melphalan alone at 200 mg/m2 versus melphalan 140 mg/m2 plus 8 Gy TBI showed survival at 45 months to be 66% for patients receiving melphalan alone and 45% for patients receiving melphalan and TBI.25 In another strategy, the French Intergroup compared a single autologous SCT after melp…”
Efficacy of Up-Front Treatment with a Double Stem Cell Transplantation in Multiple Myeloma
Eom, K., Min, C., Lee, S., Kim, Y., Kim, S., Kim, H., Lee, J., Min, W.-S., & Kim, C.-C. (2006) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyl041 · Cited by 8
Karaszewski, K., Góra, J., Ploch, W., & Wiktor-Jędrzejczak, W. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10912-w · Cited by 8
“Tandem auto-HCT was superior to single auto-HCT in MM patients in terms of OS and PFS [9].”
Efficient Allocation of Novel Agents in Multiple Myeloma: A Work in Progress
Gaultney, J. G., & Groot, C. A. U. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0484 · Cited by 8
Modi, D., Chi, J., Kim, S., Ayash, L. J., Alavi, A., Kin, A. D., Ratanatharathorn, V., Uberti, J. P., & Deol, A. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1749603 · Cited by 7
Transplant in myeloma: who, when, and why?
Perrot, A. (2024) · Hematology · doi:10.1182/hematology.2024000580 · Cited by 10
Wang, Y.-N., Zhang, C.-W., Gao, Y.-X., & Ge, X.-L. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251321349 · Cited by 8
Initial Treatment of Transplant Candidates With Multiple Myeloma
Moreau, P., & Touzeau, C. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.006 · Cited by 7
Wang, J., Zhang, Q., Zhou, R., Chen, B., & Ouyang, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033388 · Cited by 7
“High-dose therapy with tandem autologous stem-cell rescue is effective for treating high-risk neuroblastoma [32] and multiple myeloma [33] with encouraging long-term survival.”
BackgroundCurrent diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma
Ravi, G., & Gonsalves, W. I. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100444 · Cited by 8
“(47) The STAMINA phase III trial comparing single versus tandem ASCT did not show any improvement in PFS (59% vs 58%) or OS (82% vs 85.”
Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma
Nunnelee, J. S., Cottini, F., Zhao, Q., Faisal, M. S., Elder, P., Rosko, A. E., Bumma, N., Khan, A., Umyarova, E. R., Devarakonda, S. S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195794 · Cited by 8
Sauer, S., Kriegsmann, K., Nientiedt, C., Schmitt, A., Müller‐Tidow, C., Raab, M., & Kauer, J. (2023) · Transfusion Medicine and Hemotherapy · doi:10.1159/000529691 · Cited by 8
Yang, X., Yao, G., Yang, Y., Han, Y., Yang, L., & Zhang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36311 · Cited by 6
[Hematopoietic stem cell transplantation in multiple myeloma].
Vela‐Ojeda, J., & Esparza, M. A. G.-R. (2005) · PubMed · Cited by 7
Transplants for the elderly in myeloma
Morgan, G. J. (2013) · Blood · doi:10.1182/blood-2013-07-510941 · Cited by 8
Schmidmaier, R., Then, C., Schnabel, B., Oduncu, F. S., Baumann, P., & Straka, C. (2011) · Cytotherapy · doi:10.3109/14653249.2011.579960 · Cited by 8
Devadas, S. K., Khairnar, M., Hiregoudar, S., Ojha, S. K., Punatar, S. B., Gupta, A., Gokarn, A. G., Bhole, P., Kannan, S., & Khattry, N. (2017) · Blood Research · doi:10.5045/br.2017.52.4.307 · Cited by 7
“A second autologous stem cell transplantation procedure conducted after relapse is considered to be a standard practice in patients with multiple myeloma, while tandem transplants are less common at present [7-9].”
BackgroundBloodless tandem autologous transplant in Jehovah’s Witness patients
Khan, R., Mott, S. L., Schultz, A., Jethava, Y. S., & Tricot, G. J. K. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0132-6 · Cited by 7
Sauer, S., Hieke, L., Brandt, J., Müller‐Tidow, C., Schmitt, A., Kauer, J., & Kriegsmann, K. (2023) · Transfusion Medicine and Hemotherapy · doi:10.1159/000530056 · Cited by 7
Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma
Kikuchi, T., Mori, T., Koda, Y., Kohashi, S., Kato, J., Toyama, T., Nakazato, T., Aisa, Y., Shimizu, T., & Okamoto, S. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1873-2 · Cited by 7
Stevenson, J. D., Wall, C., Patel, A. D., & Lim, J. (2014) · Orthopaedics and Trauma · doi:10.1016/j.mporth.2014.05.007 · Cited by 7
Tanimura, A., Hirai, R., Nakamura, M., Takeshita, M., Hagiwara, S., & Miwa, A. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2408-4 · Cited by 9
“Indeed, the benefits of tandem ASCT were observed in patients who did not show very good responses to induction therapies [29, 30].”
BackgroundHolstein, S. A., Suman, V. J., Owzar, K., Santo, K., Benson, D. M., Shea, T. C., Martin, T. G., Magalhaes-Silverman, M. D., Isola, L. M., Vij, R., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.03.028 · Cited by 7
The Principles and Overview of Autologous Hematopoietic Stem Cell Transplantation
Vaughan, W. P., Seshadri, T., Bridges, M., & Keating, A. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-78580-6_2 · Cited by 7
New questions about transplantation in multiple myeloma.
Hari, P., Pasquini, M. C., & Vesole, D. H. (2006) · PubMed · Cited by 7
Abdelkefi, A., Maamar, M., Torjman, L., Ladeb, S., Lakhal, A., Othman, T. B., Slama, H., Jenhani, F., Mojaat, N., Hamed, L. B., et al. (2006) · Journal of Clinical Apheresis · doi:10.1002/jca.20074 · Cited by 7
“Peripheral blood progenitor cells (PBPCs) collected by apheresis after mobilisation with chemotherapy and Granulocyte-Colony Stimulating Factor (G-CSF) are a standard source of autologous support after myeloablative chemotherapy for the treatment of multiple myeloma [1,2].”
BackgroundRisk factors for relapse after complete remission with high-dose therapy for multiple myeloma
Qazilbash, M. H., Saliba, R. M., Aleman, A., Lei, X. J., Weber, D., Carrasco, A., Champlin, R. E., & Giralt, S. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500520806 · Cited by 7
Singhal, S., & Mehta, J. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0011-7 · Cited by 7
Papadopoulos, K. P., Noguera-Irizarry, W., Wiebe, L. A., Hesdorffer, C. S., Garvin, J. H., NICHOLS, G. L., Vahdat, L. T., Lo, K. M. S., Skerrett, D., Bernstein, D. S., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705103 · Cited by 7
“Tandem transplantation as a strategy to improve efficacy was demonstrated in myeloma by Barlogie et al(13) and Attal et al.(14) In an attempt to improve outcome in patients with high-risk lymphoma, our group examined the tolerability and efficacy of two regimens, first, mitoxantrone and melphalan (MMt) and second, eto…”
In vivo and in silico studies on single versus multiple transplants for multiple myeloma
Dingli, D., Pacheco, J. M., Dispenzieri, A. A., Hayman, S. R., Kumar, S. K., Lacy, M. Q., Gastineau, D. A., & Gertz, M. A. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00450.x · Cited by 7
“urvival of patients with multiple myeloma (MM) has improved with the advent of high-dose therapy (HDT) with autologous stem cell transplantation (ASCT).(1‐5) When compared to conventional therapy, HDT is associated with a significantly higher incidence of complete response (CR) that translates into a longer time to pr…”
BackgroundInfluentialEmerging Trends in the Clinical Use of Bortezomib in Multiple Myeloma
Richardson, P. G. G., Schlossman, R. L., Mitsiades, C. S., Hideshima, T., Munshi, N. C., & Anderson, K. C. (2005) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2005.n.033 · Cited by 7
Novitzky, N., Thomson, J., Thomas, V., du Toit, C., Mohamed, Z., & McDonald, A. B. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.04.002 · Cited by 8
A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
Lee, K., Yun, T., Song, E. K., Na, I. I., Shin, H., Bang, S., Lee, J. H., Lee, S., Kim, J. H., Yoon, S., et al. (2005) · Journal of Korean Medical Science · doi:10.3346/jkms.2005.20.4.598 · Cited by 7
Autologous stem cell transplantation in hematological malignancies
Gorin, N. C. (2004) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0172-4 · Cited by 7
“A recent finding has been that dexamethasone alone is almost as effective as VAD, and avoids the toxicity of vincristine and anthracyclins.”
MethodInfluentialLee, C.-K., Zangari, M., Fassas, A., Thertulien, R., Talamo, G., Badros, A. Z., Cottler‐Fox, M., van Rhee, F., Barlogie, B., & Tricot, G. J. K. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705267 · Cited by 7
Drug Combinations with Transplantation for Myeloma
Jethava, Y. S., Barlogie, B., & Tricot, G. J. K. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705671 · Cited by 7
Rabin, N. K., Percy, L. A., Khan, I., Quinn, J., D’Sa, S., & Yong, K. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09188.x · Cited by 7
“Approaches to deepen the disease response and extend progression-free survival (PFS) following high dose therapy (HDT) as part of planned upfront treatment of younger patients with symptomatic multiple myeloma (MM) have been explored since the 1990s, but no strategy has been adopted as standard of care.”
BackgroundInfluentialEom, H., Min, C.-K., Cho, B.-S., Lee, S., Lee, J. W., Min, W. S., Kim, C.-C., Kim, M., & Kim, Y. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp046 · Cited by 6
on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT), Fuchida, S., Sunami, K., Matsumoto, M., Okumura, H., Murayama, T., Miyamoto, T., Otsuka, E., Fujishima, N., Izumi, T., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2543-y · Cited by 6
Galligan, D. C., Williamson, S., Myers, J., Silbermann, R. W., Medvedova, E., Nagle, S. J., Schachter, L. G., Chen, A., Scott, E. C., & Maziarz, R. T. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.08.008 · Cited by 6
Suzuki, K., Mizuno, S., Shimazu, Y., Fuchida, S., Hagiwara, S., Itagaki, M., Nishiwaki, K., Hangaishi, A., Karasuno, T., Kikuchi, T., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13922 · Cited by 6
“For the first time, tandem ASCT resulted in long progression-free survival (PFS) and OS compared with single ASCT in the IFM 99–04 trial.(10) In contrast, the OS-improving benefit of tandem ASCT was unclear compared with single ASCT before PIs and IMiDs were available according to a metaanalysis.”
BackgroundResultAllogeneic Stem Cell Transplantation and Targeted Immunotherapy for Multiple Myeloma
Danylesko, I., Shimoni, A., & Nagler, A. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.05.021 · Cited by 6
Iacobelli, S., Apperley, J. F., & Morris, C. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.06.007 · Cited by 6
Straka, C., Knop, S. T., Vogel, M., Müller, J., Kropff, M. H., Metzner, B., Langer, C., Sayer, H. G., Jung, W. E., Dürk, H., et al. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13281 · Cited by 6
Murakami, H., Kasamatsu, T., Murakami, J., Kiguchi, T., Kanematsu, T., Ogawa, D., Takamatsu, H., Handa, H., Ozaki, S., Miki, H., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02607-z · Cited by 7
Ladbury, C. J., Somlo, G., Dagis, A., Yang, D., Armenian, S. H., Song, J. Y., Sahebi, F., Spielberger, R. T., Popplewell, L. L., Parker, P. M., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.04.022 · Cited by 6
Toubai, T., Hirate, D., Shono, Y., Ota, S., Ibata, M., Mashiko, S., Sugita, J., SHIGEMATSU, A., MIURA, Y., Kato, N., et al. (2007) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2007.00903.x · Cited by 6
“Moreover, a tandem therapeutic regimen of HDT with ASCT may be more beneficial than a single use of HDT with ASCT (Attal et al., 2003).”
BackgroundChihara, D., Sakamoto, T., Arimoto‐Miyamoto, K., Kishimoto, W., Takeoka, T., Tsuji, M., & Ohno, T. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.2922 · Cited by 6
Labidi‐Galy, S. I., Sebban, C., Ghesquières, H., Nicolas, E. V., & Biron, P. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0152-x · Cited by 6
“Double autologous SCT after conventional chemotherapy is a consolidation regimen that improves response rates, duration of response and survival among young patients with multiple myeloma (MM) [2].”
BackgroundHertenstein, B., & Ganser, A. (2004) · Der Internist · doi:10.1007/s00108-004-1287-3 · Cited by 6
Gritsaev, S. V., Kuzyaeva, A. A., & Бессмельцев, С. С. (2017) · Clinical oncohematology · doi:10.21320/2500-2139-2017-10-1-7-12 · Cited by 6
“Выполнение аутоТГСК позволяет существенно уменьшить объем клеток патологического клона, повысить качество ответа, снизить вероятность рецидива и, как следствие, улучшить показатели беспрогрессивной и, нередко, общей выживаемости [4, 5].”
Putkonen, M., Rauhala, A., Itälä, M., Kauppila, M., Pelliniemi, T., & Remes, K. (2005) · PubMed · Cited by 6
Transplantation for Myeloma — Now or Later?
Schiffer, C. A., & Zonder, J. A. (2017) · New England Journal of Medicine · doi:10.1056/nejme1700453 · Cited by 6
Orchard, K. H., Langford, J. H., Guy, M., Lewis, G., Michopoulou, S. K., Cooper, M. S., Zvavamwe, C., Richardson, D. S., & Lewington, V. J. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02317-z · Cited by 6
“The use of tandem autologous transplantation allows dose intensi fi cation by performing two procedures temporally close, shown in some trials to result in improved outcomes [21 – 23] but at the expense of increased toxicity [24].”
BackgroundSociety of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma
Richter, J. R., & Jagannath, S. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.09.003 · Cited by 6
“The IFM-94 trial evaluated single versus tandem AutoSCT and demonstrated an OS benefit for the tandem group for patients without a very good partial response to the first transplantation.(20)”
Li, H., Zheng, Y., Gao, K., & Tian, C. (2024) · Hematology · doi:10.1080/16078454.2024.2343164 · Cited by 10
“…that tandem autologous HSCT (auto-HSCT) could bring benefits to overall survival (OS) and progression-free survival (PFS) for MM patients compared to single auto-HSCT [7,8], however, some studies hold the opposite attitude, so the clinical application of tandem auto-HSCT is still controversial.”
Breitkreutz, I., Becker, N., Benner, A., Kosely, F., Heining, C., Hillengaß, J., Egerer, G., Ho, A. D., Goldschmidt, H., & Raab, M. S. (2015) · Hematological Oncology · doi:10.1002/hon.2199 · Cited by 5
Lamm, W. W., Wohlfarth, P., Bojić, M., Schoergenhofer, C., Drach, J. W., Gisslinger, H., Worel, N., Schiefer, A. I., Schulenburg, A., Agis, H., et al. (2015) · Oncology · doi:10.1159/000437055 · Cited by 5
Jamshed, S., Fowler, D. H., Neelapu, S. S., Dean, R. M., Steinberg, S. M., Odom, J., Bryant, K., Hakim, F. T., & Bishop, M. R. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.173 · Cited by 5
Bergantim, R., Trigo, F., & Guimarães, J. E. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-35 · Cited by 5
“The IFM94 study showed that the only parameter that could predict the performance of a second transplant would be the answer to the first transplant [43], which was later confirmed by another study by an Italian group [41].”
ResultMulti-omics tumor profiling technologies to develop precision medicine in multiple myeloma
Ovejero, S., & Moreaux, J. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00034 · Cited by 8
Holstein, S. A., Liu, H., & McCarthy, P. L. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.08.010 · Cited by 5
Evolving role of high dose stem cell therapy in multiple myeloma
Gupta, A. K., & Kumar, L. (2011) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.81885 · Cited by 6
Pelus, L. M., & Farag, S. S. (2011) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s6713 · Cited by 7
“Furthermore, at least a subset of MM patients, who achieve less than a very good partial response, may benefit from tandem ASCT.(8,9) While the role of ASCT in the”
InfluentialMunshi, N. C., & Jagannath, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00086-x · Cited by 6
Kong, J. H., Hu, Y., Kong, S., Lee, S., Eom, H., Lee, H., Lee, E., & Shim, H. (2020) · Journal of Clinical Apheresis · doi:10.1002/jca.21855 · Cited by 5
“of chemotherapy cycles before mobilization 6 (2-41) 8 (2-30) 5 (2-41)”
BackgroundRole of transplantation in treatment of multiple myeloma in era of novel agents
Małecki, B., Gil, L., & Dytfeld, D. (2021) · Acta Haematologica Polonica · doi:10.5603/ahp.2021.0013 · Cited by 5
The emergence of cellular therapy: impact on transfusion medicine
Snyder, E. L., & Choate, J. D. (2010) · Transfusion · doi:10.1111/j.1537-2995.2010.02878.x · Cited by 5
“Myeloma patients often need to have a double dose (10 ¥ 10(6) cells/kg) collected, to permit two transplants.(5) These three events when put together have provided the mechanisms for stimulating production of ABBREVIATIONS: CT = cellular therapy; NBF = National Blood Foundation; NMDP = National Marrow Donor Program; P…”
BackgroundThe evolving background for high-dose treatment for myeloma
Sirohi, B., Powles, R., Harousseau, J., & Anderson, K. C. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705867 · Cited by 5
Self-citationState-of-the-Art Management of Complications of Myeloma and Its Treatment
Hartley-Brown, M. A., Sullivan, D. M., & Baz, R. (2010) · Advances in Hematology · doi:10.1155/2010/343089 · Cited by 6
Costa, L. J., Kumar, S. K., Dispenzieri, A. A., Hayman, S. E., Buadi, F. K., Dingli, D., Litzow, M. R., Gertz, M. A., & Lacy, M. Q. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902803644 · Cited by 6
From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma
Zhang, S., & Farag, S. S. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.584869 · Cited by 5
“While high-dose chemotherapy with stem cell support increases the proportion of complete responses, the effect on prolongation of overall survival remains relatively modest, and all patients invariably relapse [1,4-7].”
BackgroundMcKibbin, T., Burzynski, J. A., Greene, R. E., Ochoa-Bayona, J. L., Tsai, T. W., Callander, N. S., & Freytes, C. O. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701665970 · Cited by 5
One or two autografts for myeloma?
Mehta, J. (2008) · Blood · doi:10.1182/blood-2007-12-127704 · Cited by 5
Consensus guidelines for ‘rainy day’ autologous stem cell harvests in New South Wales
Trotman, J., Presgrave, P., Kwan, Y. L., Tiley, C., Estell, J. A., Watson, A.-M., O'Brien, T. A., & Peters, D. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01632.x · Cited by 5
Allografting or Autografting for Myeloma
van Rhee, F., Crowley, J. J., & Barlogie, B. (2007) · New England Journal of Medicine · doi:10.1056/nejmc076161 · Cited by 5
AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA
Harousseau, J. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511551901.008 · Cited by 5
Self-citationKořen, J., Špıčka, I., Straub, J., Vackova, B., Trnková, M., Pohlreich, D., Pytlík, R., & Trněný, M. (2010) · PubMed · Cited by 4
Suzuki, K., Gunji, T., Kawashima, M., Uryu, H., Nagao, R., Momoki, M., Yokoyama, H., Ishii, H., Tanoue, S., Saito, T., et al. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03682-z · Cited by 4
“Developed before the novel agent era, tandem ASCT improved not just PFS, but also OS [17]; however, a meta-analysis showed that it did not enhance OS [18].”
Dou, X., Ren, J., Li, J., Liu, X., Bao, L., Chen, Y., Zhao, P., Zhong, Y., Peng, N., Wen, L., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70573 · Cited by 5
Controversies in Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma
Bhatnagar, B., & Ashraf, Z. (2013) · InTech eBooks · doi:10.5772/54115 · Cited by 4
Gay, F., Cavallo, F., & Palumbo, A. (2015) · Drugs · doi:10.1007/s40265-015-0367-0 · Cited by 5
“Results of a subgroup analysis of one of those trials, reported an improved OS only in patients achieving less than a VGPR after the first ASCT [28].”
Wang, L., Cui, J., Liu, L., & Sheng, Z. (2011) · Hematological Oncology · doi:10.1002/hon.1025 · Cited by 4
“2006 [8] 597/260 E Tandem AST then Pami +T 28 38 1.”
MethodTreatment of Transplant-Eligible Patients with Multiple Myeloma in 2014
Landau, H. J., & Giralt, S. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.004 · Cited by 5
Management of high-risk Myeloma: an evidence-based review of treatment strategies
Lehners, N., Hayden, P. J., Goldschmidt, H., & Raab, M. S. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1204908 · Cited by 4
“A randomized controlled trial examining the effect of double as opposed to single upfront autoSCT in the conventional chemotherapy era revealed a significantly prolonged OS in patients who underwent double autoSCT; this effect was also seen in patients with elevated β2M or an elevated LDH [94].”
BackgroundInfluentialTransplantation for Multiple Myeloma
Jethava, Y. S., & van Rhee, F. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_13 · Cited by 5
Abdejlil, N. B., Belloumi, D., Maammar, M., Fatimi, R. E., Torjman, L., Lakhal, A., Jenhani, F., Hmida, S., Othman, T. B., & Ladeb, S. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.246 · Cited by 4
Larsen, J. T. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.09.020 · Cited by 4
Metadata
- Authors
- Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B., & Bataille, R.
- Affiliations
- Hôpital Purpan (FR)
- Hôpital Claude Huriez (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Henri Becquerel (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Albert Michallon (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-25
- Volume
- 349
- Issue
- 26
- Pages
- 2495-2502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1982499121
- Cited by
- 984
- References
- 16
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 33 · 2019: 18 · 2018: 35 · 2017: 28 · 2016: 24 · 2015: 37 · 2014: 38 · 2013: 53 · 2012: 42
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, autologous stem cell transplantation, high-dose chemotherapy, overall survival, event-free survival, very good partial response, beta2-microglobulin, lactate dehydrogenase, prognostic factors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Transplantation, Autologous, Vincristine, Survival Rate, Multivariate Analysis, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.